tiprankstipranks
Advertisement
Advertisement

KYNB Stock Latest News

Kyntra Bio initiated with an Outperform at Oppenheimer
The FlyKyntra Bio initiated with an Outperform at Oppenheimer
25d ago
KYNB
Kyntra Bio Shareholders Back Board, Pay and Auditor
PremiumCompany Announcements
Kyntra Bio Shareholders Back Board, Pay and Auditor
2M ago
8K
KYNB
Kyntra Bio to present additional MATTERHORN trial data at EHA
PremiumThe Fly
Kyntra Bio to present additional MATTERHORN trial data at EHA
2M ago
KYNB
Kyntra Bio Receives Final Payment for China Divestiture
PremiumCompany Announcements
Kyntra Bio Receives Final Payment for China Divestiture
2M ago
8K
KYNB
Kyntra Bio initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
Kyntra Bio initiated with a Buy at Rodman & Renshaw
2M ago
KYNB
Kyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026
PremiumCompany AnnouncementsKyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026
3M ago
KYNB
FibroGen Earnings Call Highlights Clinical Momentum, Runway
Premium
Company Announcements
FibroGen Earnings Call Highlights Clinical Momentum, Runway
3M ago
KYNB
Kyntra: Advancing Oncology and LR-MDS Programs with Strong Cash Position; Buy Rating and $43 Price Target Reiterated
Premium
Ratings
Kyntra: Advancing Oncology and LR-MDS Programs with Strong Cash Position; Buy Rating and $43 Price Target Reiterated
3M ago
KYNB
FGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
FGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
KYNB
Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift
PremiumCompany Announcements
Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift
4M ago
8K
KYNB
FibroGen Earnings Call: Cash-Rich, Data-Heavy, Unproven
PremiumCompany Announcements
FibroGen Earnings Call: Cash-Rich, Data-Heavy, Unproven
5M ago
KYNB
Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio
PremiumRatings
Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio
5M ago
KYNB
Maintaining a Hold on Kyntra Bio Amid Pipeline Refocus and Pending Clinical Inflection Points
PremiumRatingsMaintaining a Hold on Kyntra Bio Amid Pipeline Refocus and Pending Clinical Inflection Points
5M ago
KYNB
FGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
FGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
KYNB
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246
Premium
The Fly
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246
5M ago
KYNB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >